N4 Pharma PLC
0GO
Company Profile
Business description
N4 Pharma PLC is the holding company for N4 UK. N4 UK is a specialist pharmaceutical company engaged in the development of nanoparticle silica delivery systems to improve the cellular delivery and potency of cancer treatments and vaccines. The company operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec and its liptide platform called ECP105.
Contact
C/o Arch Law Limited
8 Bishopsgate
Huckletree Bishopsgate
LondonEC2N 4BQ
GBRSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
stocks
Here’s 3 Top Rated ASX shares for 2026
As we start the new year, let’s take a closer look at three compelling opportunities on the ASX
stocks
Undervalued Aussie e-commerce winner
Shares attractive due to near term profit margin increase and structural growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,046.50 | 22.30 | 0.25% |
| CAC 40 | 8,233.92 | 3.51 | -0.04% |
| DAX 40 | 25,122.26 | 230.06 | 0.92% |
| Dow JONES (US) | 48,996.08 | 466.00 | -0.94% |
| FTSE 100 | 10,048.21 | 74.52 | -0.74% |
| HKSE | 26,148.34 | 310.61 | -1.17% |
| NASDAQ | 23,584.28 | 37.10 | 0.16% |
| Nikkei 225 | 51,117.26 | 844.72 | -1.63% |
| NZX 50 Index | 13,716.86 | 1.84 | 0.01% |
| S&P 500 | 6,920.93 | 23.89 | -0.34% |
| S&P/ASX 200 | 8,720.80 | 18.20 | 0.21% |
| SSE Composite Index | 4,082.98 | 2.79 | -0.07% |